March 10, 2018 9:22am
Q4 and FT 17 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
| COMPANY | SYMBOL | NET INCOME | Q4/17 LOSS | Q4/17 LPS | Q4/17 CASH |
|---|---|---|---|---|---|
| Aduro Biotech, Inc. | ADRO |
-$26.1 M $91.9 M (FY17) |
-$0.34 -$1.26 |
$349.7 M | |
| Applied Genetic Technologies | AGTC | -$5.2 M (Q2) | -$0.29 | $119.7 M | |
| Asterias Biotherapeutics | AST |
-$5.5 M -$28.4 M (FY17) |
-$0.12 -$0.56 |
$21.6 M | |
| Athersys, Inc. | ATHX |
-$13.1 M -$32.2 M (FY17) |
-$0.11 -$0.29 |
$29.3 M +$31.1 M (3/13) |
|
| Adverum Biotechnologies, Inc. | ADVM |
-$14.5 M -$56.1 M (FY17) |
-$0.32 -$1.29 |
$190.5 M | |
| AxoGen, Inc. | AXGN |
-$2.5 M -$10.4 M (FY17) |
-$0.07 -$0.31 |
$36.5 M | |
| Bellicum Pharmaceuticals, Inc. | BLCM |
-$21.9 M -$91.8 M (FY17) |
-$0.66 -$2.89 |
$106.5 M | |
| BioLife Solutions, Inc. | BLFS |
-$664 K -$1.728 M (FY17) |
-$0.05 -$0.21 |
$6.6 M | |
| Biostage, Inc. | BSTG |
-$1.2 M -$11.9 M (FY17) |
-$0.61 -$6.63 |
$4 M | |
| BioTime, Inc. | BTX |
-$71,9 M -$20 M (FY17) |
-$0.58 -$0.17 |
$38.2 M | |
| bluebird bio | BLUE |
-$117.2 M -$335.6 M (FY17) |
-$2.52 -$7.71 |
$1.6 B | |
| Brainstorm Cell Therapeutics Inc. | BCLI |
N/A -$.95 M |
N/A -$0.26 |
$7.75 M | |
| Caladrius Biosciences. | CLBS |
-$4 M -$16.2 M |
-$0.40 -$1.78 |
$60.1 M | |
| Capricor | CAPR | +$12.3 M |
-$2.4 M |
+$0.42 -$0.09 |
$14.1 M |
| Cellectis SA | CLLS |
-$16.4 M -$50.4 M (FY17) |
-$0.46 -$1.41 |
$297 M | |
| Cesca Therapeutics, Inc | KOOL | -$2.3 M (Q2) | -$0.23 | $3.5 M | |
| Cytori Therapeutics, Inc. | CYTX |
-$4.3 M -$22.64 M (FY17) |
-$0.10 -$0.82 |
$9.6 M | |
| Fate Therapeutics, Inc. | FATE |
-$12.4 M -$41.9 M (FY17) |
-$0.29 -$1.02 |
$100.9 M | |
| Fibrocell Science, Inc. | FCSC |
Q4 Not disclosed -$20.8 M (FY17) |
N/D -$1.23 |
$17.4 M | |
| Histogenics Corporation | HSGX |
-$6.1 M -$22.5 M (FY17) |
-$0.26 -$0.99 |
$8 M +$14.9 (1/18) |
|
| ImmunoCellular Therapeutics, Ltd. | IMUC |
-$4.31 M -$17.7 M (FY17) |
-$0.01 -$1.23 |
$6.6 M | |
| International Stem Cell | ISCO |
Q4 Not Disclosed -$6.06 M (FY17) |
N/A -$1.46 |
$304 K | |
| Intrexon Corporation | XON |
-$27.3 M -$117 M (FY17) |
-$0.23 -$0.98 |
$74.4 M | |
| Mesoblast Limited | MESO | -$13.7 M (Q2) | -$2.91 | $47.4 M | |
| MiMedx Group, Inc | MDXG | ||||
| Neuralstem, Inc. | CUR |
Q Not disclosed -$15.7 M |
N/D -$1.20 |
$11.7 M | |
| Northwest Biotherapeutics, Inc. | NWBO | -$73 M (FY17) | -$0.31 | $11.7 M | |
| Organovo Holdings, Inc. | ONVO | -$7.8 M (Q3) | -$0.08 | $47.3 M | |
| Osiris Therapeutics, Inc. | OSIR | ||||
| Pluristem Therapeutics, Inc. | PSTI | -$8.22 M | -$0.08 | $15.6 M | |
| ReNeuron Group PLC | RENE.L | ||||
| Regenxbio | RGNX |
-$16 M -$73.2 M (FY17) |
-$0.51 -$2.45 |
$176 M | |
| Sangamo Biosciences, Inc. | SGMO |
-$13.1 M $54.6 M (FY17) |
-$0.15 -$0.70 |
$244.6 M | |
| Spark Therapeutics, Inc. | ONCE | -$253.5 M (FY17) | -$7.63 |
$540.2 m $105 M (1/18) |
|
| Stemline Therapeutics, Inc. | STML |
-$21.7 M -$67.8 M |
-$0.93 -$2.94 |
$66.2 M +$55.5 M in new raise |
|
| uniQure N.V. | QURE |
Not Disclosed (ND) -$79.3 (FY17) |
ND -$2.94 |
$159.4 M | |
| Verastem, Inc. | VSTM |
Not disclosed (ND) -$67.8 M (FY17) |
ND -$1.76 |
$86.7 M | |
| Vericel Corporation | VCEL | +$300 K |
-$17.4 |
+$0.01 -$0.53 |
$26.9 M |
| VistaGen Therapeutics, Inc. | VTGN | -$3.5 M (Q3) | -$0.25 | $13 M |
